Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

SELUTION 4 De Novo Small Vessel IDE-proef

21 september 2026 bijgewerkt door: M.A. Med Alliance S.A.

Een prospectieve, gerandomiseerde, enkelblinde, multicenter studie om de veiligheid en effectiviteit van de SELUTION SLR™ 014 PTCA-medicatie-eluerende ballon te beoordelen bij de behandeling van proefpersonen met de novo coronaire laesies in kleine vaten

Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA.

The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.

Studie Overzicht

Gedetailleerde beschrijving

Prospective, randomized controlled, single-blind, multicenter, clinical trial

The study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.

Subjects who present with chronic coronary syndrome (CCS), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) with an indication for percutaneous coronary intervention (PCI) with planned intervention for de novo lesions in small coronary vessels (RVD 2.00 mm to 2.75 mm) and meeting all eligibility criteria will be randomized 1:1 to treatment of the identified target lesion with either the SELUTION SLR 014 PTCA DEB or contemporary DES.

Randomized Cohort:

  • Intervention (DEB Strategy): Subjects randomized to the SELUTION SLR 014 PTCA DEB arm will receive lesion preparation according to the 3rd drug coated balloon (DCB) consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, intravascular lithotripsy, laser, rotational or orbital atherectomy, cutting or scoring balloon at the discretion of the operator as needed to reduce diameter stenosis to ≤ 30%). Subjects with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis > 30%) will receive a DES instead of the SELUTION DEB but remain in the SELUTION DEB group (intention to treat analysis). The DEB should not be used after DES implant.
  • Control (DES): Subjects randomized to the DES arm will receive treatment using any FDA approved "limus-based" DES, as per standard institutional practice.

Angiographic Substudy:

The angiographic substudy is a parallel registry consisting of up to 30 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. These subjects will undergo angiography at 12 months post-procedure. Clinical follow-up will not extend beyond 12 months in this cohort.

Pharmacokinetic (pK) Substudy:

The pKsubstudy is a parallel registry consisting of up to 20 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. This study will be conducted under an approved substudy protocol and will include blood draws at regular intervals to characterize the pK plasma profile of sirolimus.

Primary Endpoint:

Target lesion failure (TLF), defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months. MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.

Studietype

Ingrijpend

Inschrijving (Geschat)

960

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Genk, België, 3600
        • ZOL Genk
      • Hasselt, België, 3500
        • Hartcentrum Hasselt Jessa Ziekenhuis
      • Bad Krozingen, Duitsland, 79189
        • Universitäts-Herzzentrum Freiburg
      • Berlin, Duitsland, 12683
        • UKB Berlin
      • Dresden, Duitsland, 01307
        • Herzzentrum Dresden
    • Arkansas
      • Jonesboro, Arkansas, Verenigde Staten, 72401
        • St. Bernards
    • California
      • Chula Vista, California, Verenigde Staten, 91911
        • CISD Sharp Chula Vista
      • Los Angeles, California, Verenigde Staten, 90048
        • Cedars Sinai
      • Thousand Oaks, California, Verenigde Staten, 91360
        • HCA Los Robles
      • Torrance, California, Verenigde Staten, 90502
        • Harbor UCLA
    • Colorado
      • Golden, Colorado, Verenigde Staten, 80401
        • Colorado Heart and Vascular
      • Thornton, Colorado, Verenigde Staten, 80023
        • ClinRe
    • Connecticut
      • New Haven, Connecticut, Verenigde Staten, 06520
        • Yale New Haven Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Verenigde Staten, 20010
        • MedStar Washington Hospital Center
    • Florida
      • Bradenton, Florida, Verenigde Staten, 34208
        • Manatee Memorial
      • Clearwater, Florida, Verenigde Staten, 34695
        • Mease Countryside Hospital
      • Jacksonville, Florida, Verenigde Staten, 32209
        • University of Florida, Jacksonville
      • Largo, Florida, Verenigde Staten, 33770
        • HCA Largo
      • Orlando, Florida, Verenigde Staten, 32803
        • AdventHealth Orlando
      • St. Petersburg, Florida, Verenigde Staten, 33709
        • HCA Northside
      • Trinity, Florida, Verenigde Staten, 34655
        • HCA Trinity
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30309
        • Piedmont Heart Institute
      • Atlanta, Georgia, Verenigde Staten, 30033
        • Atlanta VA
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Emory
      • Dalton, Georgia, Verenigde Staten, 30720
        • Hamilton Medical Center
      • Thomasville, Georgia, Verenigde Staten, 31792
        • Archbold Memorial Hospital
    • Hawaii
      • ‘Aiea, Hawaii, Verenigde Staten, 96701
        • Pali Momi Medical Center
    • Illinois
      • Downers Grove, Illinois, Verenigde Staten, 60515
        • Advocate Good Samaritan Hospital
      • Oak Lawn, Illinois, Verenigde Staten, 60453
        • Advocate Christ Medical Center
      • Urbana, Illinois, Verenigde Staten, 61801
        • Carle Foundation Hospital
    • Iowa
      • Iowa City, Iowa, Verenigde Staten, 52242
        • University of Iowa Medical Center
    • Kansas
      • Wichita, Kansas, Verenigde Staten, 67226
        • Cardiovascular Research Institute of Kansas
    • Kentucky
      • Lexington, Kentucky, Verenigde Staten, 40503
        • Baptist Health Lexington
    • Louisiana
      • Houma, Louisiana, Verenigde Staten, 70360
        • Cardiovascular Institute of the South
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21201
        • University of Maryland
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Brigham & Women's
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Mass General
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Beth Israel Deaconess
      • Springfield, Massachusetts, Verenigde Staten, 01199
        • Baystate Medical Center
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55417
        • Minneapolis VA Medical Center
      • Minneapolis, Minnesota, Verenigde Staten, 55407
        • Minneapolis Heart Institute
    • Mississippi
      • Tupelo, Mississippi, Verenigde Staten, 38801
        • North Mississippi Medical Center
    • Missouri
      • Overland Park, Missouri, Verenigde Staten, 66211
        • HCA Overland Park
      • St Louis, Missouri, Verenigde Staten, 63136
        • St. Louis Heart and Vascular
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68198
        • University of Nebraska
    • New Jersey
      • Englewood, New Jersey, Verenigde Staten, 07631
        • Englewood Health
    • New York
      • New York, New York, Verenigde Staten, 10029
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Verenigde Staten, 10075
        • Northwell Health Lenox Hill
      • Stony Brook, New York, Verenigde Staten, 11794
        • Stony Brook University Hospital
    • North Carolina
      • Raleigh, North Carolina, Verenigde Staten, 27607
        • NC Heart and Vascular
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45219
        • The Lindner Research Center at Christ
      • Cleveland, Ohio, Verenigde Staten, 44120
        • UH Cleveland
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73120
        • Oklahoma Heart
    • Pennsylvania
      • Hershey, Pennsylvania, Verenigde Staten, 17033
        • Penn State Health Hershey & Berks
      • Mechanicsburg, Pennsylvania, Verenigde Staten, 17050
        • UPMC Pinnacle
      • York, Pennsylvania, Verenigde Staten, 17403
        • WellSpan York Hospital
    • Rhode Island
      • Providence, Rhode Island, Verenigde Staten, 02903
        • Lifespan Rhode Island & Miriam
    • Tennessee
      • Chattanooga, Tennessee, Verenigde Staten, 37404
        • CHI Memorial
      • Chattanooga, Tennessee, Verenigde Staten, 37404
        • University of Nebraska
      • Nashville, Tennessee, Verenigde Staten, 37203
        • HCA Centennial
    • Texas
      • Abilene, Texas, Verenigde Staten, 79601
        • Hendrick Health
      • Dallas, Texas, Verenigde Staten, 75231
        • Texas Health
      • Dallas, Texas, Verenigde Staten, 75246
        • Baylor Scott and White - Dallas
      • Fort Worth, Texas, Verenigde Staten, 76104
        • Medical City of Fort Worth
      • Plano, Texas, Verenigde Staten, 75093
        • Baylor Scott and White Plano
      • Temple, Texas, Verenigde Staten, 76508
        • Baylor Scott and White - Temple
    • Utah
      • Murray, Utah, Verenigde Staten, 84107
        • Intermountain Health - Salt Lake City
    • Virginia
      • Richmond, Virginia, Verenigde Staten, 23225
        • HCA Chippenham
    • West Virginia
      • Charleston, West Virginia, Verenigde Staten, 25304
        • CAMC
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53215
        • Advocate Aurora St. Luke's

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Clinical Inclusion Criteria

Subjects must meet all of the following clinical criteria to participate in the trial:

  1. Subject is ≥ 18 years (or the minimum legal age as required by local regulations).
  2. Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days before the procedure or are using a contraceptive device or drug.
  3. Subject presents with chronic coronary syndromes [CCS] (manifest as documented angina or positive functional testing), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) (biomarkers stabilized or down trending) with an indication for PCI and planned intervention.
  4. Subject can tolerate dual antiplatelet therapy with aspirin, plus either Clopidogrel, Prasugrel, or Ticagrelor. (Note: For subjects requiring oral anticoagulation, aspirin may be omitted based on investigator discretion).
  5. Subject has life expectancy > 1 year in the opinion of the investigator.
  6. Subject is willing and able to provide informed consent and comply with study procedures and required follow-up evaluations.

PK Sub- Study Inclusion Criteria:

Subjects must meet all of the main protocol inclusion criteria to participate in the PK sub-study. Subjects must also meet the following additional PK sub-study inclusion criteria:

1. Subject is willing and able to provide informed consent for the PK sub-study and comply with the PK sub-study procedures and required follow-up evaluations.

Imaging Inclusion Criteria

Subject's target lesion(s) must meet all of the following angiographic criteria for the subject to participate in the trial:

  1. A single, target lesions that meet criteria can be treated in a single vessel. No non-target lesions can be treated within the target vessel in the index procedure. Non-target lesions within the target vessel can be staged for treatment > 30 days from the index procedure.
  2. Up to two (2) non-target lesions in up to two (2) non-target vessels may be treated, but successful PCI of the non-target lesions must be completed before randomization and treatment of the target lesion.
  3. Target lesion is ≤ 36 mm in length.
  4. Target lesion has diameter stenosis > 50% and ≤ 99% with distal flow at least thrombolysis in myocardial infarction (TIMI) 2.
  5. Target vessel has RVD of ≥ 2.00 mm and ≤ 2.75 mm [by visual assessment].
  6. Target lesion is within a native coronary artery or major branch.
  7. A target lesion within a bifurcation is allowed only if a single vessel (either main vessel or side branch) is to be treated.
  8. The identified target lesion has high probability for successful treatment with approved pre-treatment techniques and DEB alone based on Investigator assessment.

Exclusion Criteria:

  • Clinical Exclusion Criteria

Subjects who meet any of the following clinical criteria will be excluded from the trial:

  1. Subject with known hypersensitivity or allergy to Sirolimus or its analogues.
  2. Subject presents with NSTEMI and rising biomarkers, or ongoing chest pain or is hemodynamically instable.
  3. Subject with history of ST-elevation myocardial infarction (STEMI) within 30 days of the index procedure.
  4. Subject with planned major surgery within 30 days following the index procedure.
  5. Subject with planned treatment of lesion involving aorto-ostial location.
  6. Subject with PCI of a non-target vessel within ± 30 days of the index procedure.
  7. Subject with history (within 6 months prior to index procedure) of New York Heart Association (NYHA) class III or IV heart failure.
  8. Subject with history of active peptic ulcer or gastrointestinal bleeding within 6 months of the index procedure or other inability to comply with the recommended duration of dual antiplatelet therapy (DAPT).
  9. Subject is pregnant, breast-feeding or a woman of childbearing potential who plans pregnancy up to 1 year following index procedure.
  10. Subjects with current documented left ventricular ejection fraction (LVEF) < 30%.
  11. Subject is considered not able to tolerate at least 30 seconds of coronary occlusion for the target lesion treated.
  12. Subjects is currently participating in another investigational drug or device study that has not completed primary endpoint follow-up.
  13. Subject with definite clinically active COVID-19 infection defined as a positive COVID test within 24 hours of index procedure.
  14. Subject has chronic renal insufficiency (dialysis dependent, or glomerular filtration rate [GFR] ≤ 30 ml/min/1.73 m2 within 30 days of index procedure) or had undergone renal transplantation.

PK Sub-Study Exclusion Criteria:

Subjects must meet none of the main protocol exclusion criteria to participate in the PK sub-study. Subjects will be excluded if any of the following additional PK sub-study exclusion criteria are met:

  1. Any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device has been placed/used in any part of the body within 3 months prior to the index procedure including non-target lesion(s) treated during the index procedure.

  2. Planned intervention with any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device anywhere in the body within 6 months after the index procedure. Note: staged procedures >30 days after index procedure (Exclusion #6 of the main protocol) are permitted only in the main protocol, and are not permitted in this PK sub-study.

  3. The subject is taking or has taken within the last 3 months any limus family medication(s) for any reason.

  4. Subject is concurrently enrolled in the main protocol angiographic registry.

  5. Subjects who are taking strong CYP3A4 Inhibitors within 14 days before the index procedure or plan to take the strong inhibitors during the study period. Strong inhibitors include: cobicistat; ritonavir; indinavir and ritonavir; itraconazole; ketoconazole; lopinavir and ritonavir; paritaprevir and ritonavir and ombitasvir (and/or dasabuvir); posaconazole; saquinavir and ritonavir; tipranavir and ritonavir; elvitegravir and ritonavir; telithromycin; voriconazole; ceritinib; clarithromycin; idealalisib; nefazodone; nelfinavir.

  6. Subjects who are taking strong CYP3A4 Inducers within 14 days before the index procedure or plan to take the strong inducers during the study period. Strong inducers include apalutamide; carbamazepine; enzalutamide; ivosidenib; lumacaftor and ivacaftor; mitotane; phenytoin; rifampin; St. John's wort.

    • Angiographic Exclusion Criteria

Subject whose target lesion(s) meet any of the following angiographic criteria will be excluded from the trial:

  1. Target lesion is totally occluded or has evidence of thrombus.
  2. Target lesion is located in the left main or any arterial or venous graft.
  3. Target lesion is in a side branch that is "jailed" by a main vessel stent.
  4. In stent restenosis

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: SELUTION SLR 014 PTCA DEB

SELUTION Sustained Limus Release (SLR) 014 Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon (DEB)

The SELUTION SLR 014 PTCA DEB is a minimally invasive, single use and sterile Sirolimus coated PTCA balloon catheter.

The SELUTION SLR 014 PTCA DEB is available with balloon diameters from 2.0 to 3.0 mm and lengths of 15 to 40 mm for the purpose of the De Novo IDE trial

After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.

Actieve vergelijker: Control Treatment

any FDA approved "limus-based" Drug Eluting Stent, as per standard institutional practice

For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.

The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain < 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Target lesion failure (TLF)
Tijdsspanne: 12 months

Target lesion failure (TLF) is defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months.

MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.

12 months
PK Sub-study Primary Endpoint 1
Tijdsspanne: 6 months

PK parameters of C(max)

6 months
PK Sub-study Primary Endpoint 2
Tijdsspanne: 6 months

PK parameters of T(max)

6 months
PK Sub-study Primary Endpoint 3
Tijdsspanne: 6 months

PK parameters of AUC(last)

6 months
PK Sub-study Primary Endpoint 4
Tijdsspanne: 6 months

PK parameters of MRT(last)

6 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Secondary Endpoint 1
Tijdsspanne: 12 months

Composite of all-cause mortality, target vessel MI or clinically driven target lesion revascularization

12 months
Secondary Endpoint 2
Tijdsspanne: Up to 7 days

Lesion success, defined as attainment of < 30% residual stenosis of target lesion using any percutaneous method

Up to 7 days
Secondary Endpoint 3
Tijdsspanne: Up to 7 days

Procedure success, defined as attainment of < 30% residual stenosis of the target lesion using the assigned study device only without the occurrence of in-hospital major adverse cardiac events (MACE), composite of all-cause death, MI or any clinically-driven TLR.

Up to 7 days
Secondary Endpoint 4
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Composite safety endpoint, defined as the patient-oriented composite of any death, any MI (spontaneous or peri-procedural), or any repeat revascularization.

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 5
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

All-Cause Mortality

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 6
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Cardiovascular Mortality

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 7
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

MI (spontaneous MI using the 4th UDMI, peri-procedural MI using SCAI and Academic Research Consortium [ARC]-2 definitions)

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 8
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Clinically-driven TLR

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 9
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

all TLR

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 10
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Clinically-driven Target Vessel Revascularization (TVR)

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 11
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

all TVR

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 12
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Non-target lesion revascularization

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 13
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

TLF

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 14
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Target vessel failure (TVF), defined as a composite of: cardiac death, target vessel MI (spontaneous or peri-procedural) and any clinically-driven TVR

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 15
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Stent or target lesion segment thrombosis (definite or probable) according to the ARC criteria for acute, subacute, late, very late and cumulative stent thrombosis

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 16
Tijdsspanne: 12 months

Bleeding Academic Research Consortium (BARC) class 2-5

12 months
Secondary Endpoint 17
Tijdsspanne: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Net adverse clinical events, defined as death, MI (spontaneous or peri-procedural), TVR, stent/target lesion segment thrombosis or bleeding (BARC types 2-5, assessed to 12 months)

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
PK Sub-Study Secondary Endpoint 1
Tijdsspanne: 6 months

If calculations are valid, additional PK parameter of AUC(inf).

6 months
PK Sub-Study Secondary Endpoint 2
Tijdsspanne: 6 months

If calculations are valid, additional PK parameter of Cl.

6 months
PK Sub-Study Secondary Endpoint 3
Tijdsspanne: 6 months

If calculations are valid, additional PK parameter of Vz.

6 months
PK Sub-Study Secondary Endpoint 4
Tijdsspanne: 6 months

If calculations are valid, additional PK parameter of Vss.

6 months
PK Sub-Study Secondary Endpoint 5
Tijdsspanne: 6 months

If calculations are valid, additional PK parameter of half-life.

6 months
PK Sub-Study Secondary Endpoint 6
Tijdsspanne: 6 months

Dose normalized C(max) will be considered if appropriate.

6 months
PK Sub-Study Secondary Endpoint 7
Tijdsspanne: 6 months

Dose normalized AUC will be considered if appropriate.

6 months
PK Sub-Study Secondary Endpoint 8
Tijdsspanne: 6 months

Device success, defined as attainment of ≤ 30% residual stenosis of the target lesion using the assigned device only

6 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Ron Waksman, MD, Medstar Health Research Institute

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 oktober 2023

Primaire voltooiing (Geschat)

1 september 2027

Studie voltooiing (Geschat)

1 september 2031

Studieregistratiedata

Eerst ingediend

30 juni 2023

Eerst ingediend dat voldeed aan de QC-criteria

7 juli 2023

Eerst geplaatst (Werkelijk)

14 juli 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

24 september 2026

Laatste update ingediend die voldeed aan QC-criteria

21 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren